| Title: |
Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. |
| Authors: |
Eid, Roland, Tarabay, Anthony, Decazes, Pierre, David, Clémence, Kerbage, Fouad, Zeghondy, Jean, Antoun, Leony, Smolenschi, Cristina, Fuerea, Alina, Valery, Marine, Boige, Valerie, Gelli, Maximiliano, Tselikas, Lambros, Durand-Labrunie, Jerome, Belkouchi, Younes, Littisha, Lawrance, Ammari, Samy, Ducreux, Michel, Lassau, Nathalie, Hollebecque, Antoine |
| Source: |
Future Oncology; Mar2025, Vol. 21 Issue 6, p691-697, 7p |
| Abstract: |
Introduction FOLFIRINOX, a primary chemotherapy for metastatic pancreatic cancer, often causes severe toxicity, necessitating hospitalization and dose adjustments. This study aims to identify predictors of FOLFIRINOX toxicity, focusing on biological, clinical, and anthropometric factors. Material & methods This retrospective study analyzes pancreatic adenocarcinoma patients on FOLFIRINOX, assessing pre-treatment biological, clinical, and anthropometric traits. Hospitalizations and tolerance during the first chemotherapy month were evaluated using CTCAE v5.0 grading, with early toxicity assessed via anthropometric factors using Anthropometer3DNet software from pre-treatment scans. Results In 152 pancreatic cancer patients (median age: 62), FOLFIRINOX was administered in metastatic (81%), locally advanced (14%), and adjuvant/neoadjuvant (5%) settings. Performance Status was zero (49%), one (41%) and ≥ 2 (10%). Median follow-up was 62.5 months, with median overall survival of 13.7 months and progression-free survival of 8.9 months. First-cycle dose reduction occurred in 14% of patients. Within the first month, 48% experienced toxicity leading to hospitalization and/or dose reduction, with 28% requiring a median 8-day hospitalization. Low muscle body mass (MBM) significantly correlated with dose reduction (AUC 0.63; p = 0.005). An NLR ratio less than 4 was significantly associated with longer OS (p = 0.001). Conclusion Low MBM is linked to FOLFIRINOX toxicity, suggesting MBM assessment could allow better selection of patients to avoid these toxicities, warranting further confirmation in larger cohorts. [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
